The addition of enzalutamide (Xtandi) to leuprolide acetate resulted in a 40.3% lower risk of death compared with leuprolide acetate alone in patients with high-risk, biochemically recurrent prostate cancer, according to the final overall…
Enzalutamide/Leuprolide Leads to 40% Lower Risk of Death in Prostate Cancer | Targeted Oncology
